Claims for Patent: 8,283,182

Summary for Patent: 8,283,182

Title:	Agglutination based sample testing device
Abstract:	A sample testing device for testing for the presence of a component of interest in a liquid sample comprises: (a) at least one capillary pathway which has an upstream end and a downstream end and which incorporates a reagent system capable of causing agglutination with said component to be detected (the test capillary); (b) preferably, but optionally, at least one capillary pathway having an upstream end and a downstream end (the control capillary); (c) a sampling region to which the liquid sample is applied and from which the sample is able to enter the upstream ends of the test capillary(s) and if present the control capillary(s); (d) a power source; (c) detection arrangements electrically associated with said power source for detecting the presence of liquid at a downstream region of said testing capillary(s) and if present the control capillary(s); (f) display means operated by said power source for indicating the result of the test; and (g) signal processing means associated with the power source, detection arrangement and display means for evaluating the result of the test and providing said result on the display means. The device may be used for a pregnancy test, more particularly for determining the presence of hCG in urine.
Inventor(s):	Bond; Damian Joseph Peter (Bacup, GB), Minter; Stephen John (New Mills, GB), Minter; Timothy John (Brighton, GB)
Assignee:	Platform Diagnostics Limited (Ossett, GB)
Application Number:	12/813,896
Patent Claims:	1. A method for testing for the presence of a component of interest in a liquid sample, comprising: (a) providing a sample testing device, wherein the device comprises: (i) at least one test capillary which has an upstream end and a downstream end and which incorporates an agglutination reagent system capable of causing agglutination with the component of interest; (ii) a sampling region for receiving the liquid sample and from which the liquid sample enters the upstream end of the test capillary; (iii) a power source; (iv) a detector electrically associated with the power source for detecting presence or absence of the liquid sample at the downstream end of the test capillary; (v) a display device operated by the power source for indicating a result of a test; and (vi) a signal processor associated with the power source, detector and display device for evaluating the result of the test and providing the result on the display device; (b) applying the liquid sample to the sampling region, whereby the liquid sample flows along the test capillary and contacts the agglutination reagent system and wherein the presence of the component of interest in the liquid sample causes agglutination that slows flow of the liquid sample such that the liquid sample does not reach the downstream end of the test capillary by a predetermined time, interval; and (c) detecting the presence or absence of the liquid sample at the downstream end of the test control capillary at the pre-determined time interval, wherein absence of the liquid sample at the downstream end of the test capillary at the pre-determined time interval is indicative of the presence of the component. 2. The method of claim 1, wherein measurement of the pre-determined time interval commences upon application of the liquid sample to the sampling region. 3. The method of claim 1, wherein the signal processor comprises a timer for measuring the pre-determined time interval. 4. The method of claim 1, wherein the sample testing device further comprises at least one control capillary having an upstream end and a downstream end, wherein the liquid sample enters the upstream end of the control capillary from the sampling region, and wherein the method further comprises detecting the presence or absence of the liquid sample at the downstream end of the control capillary at the pre-determined time interval. 5. The method of claim 4, wherein the presence of the liquid sample at the downstream end of the control capillary at the pre-determined time interval confirms that the sample testing device is functioning normally. 6. The method of claim 4, wherein the control capillary comprises a non-agglutinating reagent system. 7. The method of claim 1, wherein the power source comprises electrodes of dissimilar metals provided at the sampling region of the sample test device, the electrodes being adapted to generate a current when the liquid sample is applied to the sampling region. 8. The method of claim 7, wherein the electrodes of the dissimilar metals alternate with each other. 9. The method of claim 1, wherein the agglutination reagent system comprises beads on which is immobilized a binding partner for the component of interest. 10. The method of claim 9, wherein the binding partner is an antibody. 11. The method of claim 1, wherein the agglutination reagent system comprises a binding partner for the component of interest immobilized on walls of the test capillary. 12. The method of claim 11, wherein the binding partner is an antibody. 13. The method of claim 1, wherein the component of interest is human Chorionic Gonadotropin (hCG). 14. The method of claim 1, wherein the test capillary is formed by a co-operating plate and lid arrangement, the plate being formed with channels which become capillary tubes on location of the lid. 15. The method of claim 1, wherein the downstream end of the test capillary has at least one aperture and the detector is provided beneath the aperture. 16. The method of claim 1, wherein the detector comprises a pair of electrodes across which a potential difference is applied. 17. The method of claim 1, wherein the test capillary includes a particulate material to enhance a change in flow rate. 18. The method of claim 17, wherein the particulate material is an inert material. 19. The method of claim 18, wherein the inert particulate material is silica or bentonite. 20. The method of claim 17, wherein said particulate material is a swellable polymer.

Details for Patent 8,283,182

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2030-06-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2030-06-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2030-06-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2030-06-11